What Is Thymosin Alpha 1?

1. How does thymosin alpha 1 work?

TA1 affects communication between immune cells. Dendritic cells help detect threats and present pieces of them to T cells, which then mount more specific responses. This provides a route through which a peptide can influence both early pathogen recognition and the response that follows.

In Romani and colleagues’ 2004 experiments, TA1 promoted dendritic-cell maturation and production of interleukin-12, a signaling protein involved in T-cell responses. The researchers also found protection against a fungal infection in highly susceptible mice after hematopoietic transplantation. The work implicated Toll-like receptor signaling, part of the immune system’s threat-detection machinery.

The same research group later found regulatory effects involving TLR9 and an enzyme called IDO. These experiments involved human and mouse cells and showed pathways associated with regulatory T cells and immune tolerance. That helps explain why papers describe TA1 as an immunomodulator: its effects include regulation of inflammation as well as activation of defenses.

Neither mechanism proves that TA1 can automatically correct whatever is wrong with someone’s immune system. The effect depends on the cells, disease and experimental conditions. “Immune balance” needs a defined outcome before it can be tested in a person.

2. Thymosin alpha 1 benefits: what do human trials show?

TA1 has been tested in people, including randomized, blinded trials. The results below concern diagnosed illnesses. The percentages retain their original outcomes so that viral clearance, infection rates and survival do not get merged into a single claim about “better immunity.”

The large sepsis trial and its correction

In TESTS, deaths by day 28 occurred in 127 of 542 TA1 recipients and 132 of 547 placebo recipients. The corrected hazard ratio was 0.97, with a 95% confidence interval of 0.76–1.24. That range includes both benefit and harm; the study did not demonstrate reduced mortality.

The May 2025 correction addressed outdated trial-database values used in the original publication. The figures above use the corrected report. This trial cannot answer whether a healthy person will catch fewer colds, but it limits broad claims that TA1 reliably improves survival during severe infection.

The September 2026 hepatitis B review

Naing and colleagues’ Cochrane review, published September 9, 2026, included 10 studies with 1,349 adults. Three studies reporting deaths recorded 14 deaths among 460 TA1 recipients and 26 among 447 controls over follow-up of six to 24 months.

Those numbers favor TA1, but all included studies had methodological problems. The authors rated evidence for mortality and most other outcomes as very low certainty, and evidence for serious adverse events as low certainty. Different studies also used different additional treatments. The review leaves uncertainty about the size and reliability of any benefit; it does not supply a longevity estimate for people without hepatitis B.

3. Can TA1 prevent colds or slow immune aging?

The most relevant experiment would enroll people like the intended users and count infections, sick days or missed training sessions. A T-cell measurement alone cannot tell you how often someone will get sick.

An early double-blind vaccine study by Gravenstein and colleagues randomized 90 men aged 65–99 to TA1 or placebo alongside influenza vaccination. Researchers could analyze antibody responses in 85 men. They defined a response as a fourfold rise in antibody titer over three to six weeks.

That is a specific test of vaccine response in older men. It does not measure lifespan, biological-age reversal or year-round protection in younger adults. It also tests TA1 alongside a vaccine, so it cannot establish that TA1 replaces vaccination.

For a longevity claim, ask what changed and for how long. An antibody response, a lymphocyte count, fewer infections and longer survival are separate outcomes. The studies cited here do not establish that TA1 regrows the human thymus or extends healthy lifespan. Research on Epitalon, another peptide discussed in longevity circles, examines different mechanisms and cannot fill that gap.

4. Thymosin alpha 1 for long COVID and chronic fatigue

Acute COVID-19 studies are often cited in discussions of persistent fatigue. The participants in Shehadeh’s pilot trial were hospitalized with low oxygen levels and low lymphocyte counts. That is a different clinical setting from months of brain fog, fatigue or post-exertional symptoms.

The trial found a faster CD4 T-cell increase in the subgroup receiving low-flow oxygen. Neither oxygen subgroup had a statistically significant difference in clinical recovery. With only 49 participants and an open-label design, it was a preliminary experiment.

These results cannot establish a long-COVID treatment. A trial addressing that question needs people with persistent symptoms, a comparison group and measurements of daily function and symptom burden over time. The same applies to claims about chronic fatigue or an “immune reset.”

If you are comparing personal accounts, separate symptom changes from test results. “My lymphocyte count rose” and “I can work a full day again” describe different observations. Both may be worth documenting, but one cannot substitute for the other.

5. Thymosin alpha 1 dosage and half-life

The frequently quoted 1.6 mg dose has a clinical research history. In Mutchnick’s hepatitis B trial, participants received 1.6 mg subcutaneously twice weekly for six months, followed by another six months of observation. That trial did not confirm the hoped-for efficacy.

The TRACE trial used a more intensive schedule for acute pancreatitis: 1.6 mg every 12 hours during the first week, then daily during the second. Its main outcome also did not improve significantly. These schedules describe disease-specific experiments, not interchangeable wellness protocols.

TA1 does have human pharmacokinetic data. Rost and colleagues compared three formulations in nine healthy volunteers. Peak serum levels occurred around one to two hours after subcutaneous administration, and elimination half-life was below three hours. They found no apparent accumulation over five days of repeated dosing, although exposure differed by formulation.

Half-life describes how quickly measured drug levels decline. It does not tell you how long a downstream immune response lasts or establish a dosing interval. A half-life visualization can model blood-level assumptions; it cannot determine an effective immune-support cycle.

There is no validated TA1 dose or cycle for healthy-adult longevity, training recovery or routine cold prevention. Oral capsules and nasal sprays would also need their own absorption and outcome studies. Matching the milligrams in an injection study does not establish equivalent bioavailability.

6. Thymosin alpha 1 side effects and safety

The FDA’s clinical review describes local irritation, redness and injection-site discomfort as commonly reported reactions. It also identifies concerns in people undergoing deliberate immunosuppression. Someone taking transplant or autoimmune medication needs their treating specialist involved before considering an immune-active peptide.

The clinical record does not establish that every preparation is equally safe. FDA’s compounded-TA1 assessment raises concerns about unwanted immune reactions, peptide impurities and characterization of the active ingredient. The agency says available safety information is insufficient to define the risks of the proposed compounded product.

A purity percentage addresses a narrower question than clinical safety. It does not show whether an injection is sterile, whether its effects match the trial formulation or whether repeated use is safe for a particular person. Likewise, an uneventful short course cannot establish the risk of taking TA1 for years.

Pregnancy, breastfeeding, organ transplantation and active autoimmune disease were among the TESTS trial exclusions. Its results therefore cannot supply reassurance for those groups.

7. Is thymosin alpha 1 FDA approved?

TA1 has no FDA-approved drug product. The FDA’s assessment documents medical products in other countries and distinguishes orphan-drug designation from approval. Zadaxin is a finished product; a vial sold under the molecule’s name is not automatically the same preparation.

Orphan designation provides development incentives for a proposed rare-disease use. It does not authorize marketing. A compounding review answers another regulatory question and also does not approve a finished drug. Claims that TA1 is “FDA approved as an orphan drug” confuse those processes.

8. Thymosin alpha 1 vs TB-500 and peptide stacks

The shared word thymosin causes avoidable confusion. TA1 has 28 amino acids and an immune-focused research history. TB-500 usually refers to a fragment of thymosin beta-4, a different molecule studied in tissue-repair contexts. A trial of one cannot establish a benefit from the other.

Adding BPC-157, KPV or TB-500 to TA1 creates a new combination question. Separate papers on infection, intestinal inflammation and tissue repair do not establish that a stack improves recovery or reduces adverse effects. The trials in this guide did not test those combinations.

For anyone documenting an exposure, useful records include the exact product, dates, other medications, symptoms and any clinician-ordered measurements. If the goal is fewer illnesses, record illness episodes and days of impaired function. If the goal is less fatigue, record what daily activities were possible and whether exertion worsened symptoms afterward. Those records can support a clinical discussion without assigning TA1 credit for every change that happened during the same month.

9. Thymosin Alpha 1 FAQ

• Are TA1, thymalfasin and Zadaxin the same thing?

  TA1 abbreviates thymosin alpha 1. Thymalfasin is the synthetic peptide, while Zadaxin is a finished drug product containing it. A research vial labeled TA1 is not automatically equivalent to that product.

• What are the benefits of thymosin alpha 1?

  Researchers have measured immune-cell effects and tested TA1 in infections and other illnesses. Some trials report benefits, while larger trials have missed their main endpoints. Routine immune enhancement and longevity benefits in healthy adults remain unestablished.

• Does thymosin alpha 1 help long COVID?

  The acute COVID-19 trials discussed here do not establish treatment for long COVID. A rise in T-cell count during hospitalization cannot establish improvement in persistent fatigue, brain fog or post-exertional symptoms.

• What is the recommended thymosin alpha 1 dosage?

  There is no validated dose for general wellness or longevity. A hepatitis B trial used 1.6 mg twice weekly for six months; other indications used different schedules. These are study regimens, not a general recommendation.

• What is thymosin alpha 1's half-life?

  A small human study found an elimination half-life below three hours after subcutaneous administration, with peak levels around one to two hours. Blood clearance and duration of immune effects are different measurements.

• What side effects can thymosin alpha 1 cause?

  Reported effects include local redness, irritation and injection-site discomfort. Trial tolerability does not establish the safety of prolonged use or every commercial preparation.

• Is thymosin alpha 1 the same as TB-500?

  No. TA1 is a 28-amino-acid immune peptide. TB-500 usually refers to a fragment of thymosin beta-4 and has a separate tissue-repair research history. Their evidence and uses are not interchangeable.

• Is thymosin alpha 1 FDA approved?

  TA1 has no FDA-approved drug product. Overseas registrations, orphan-drug designations and compounding reviews are separate from US marketing approval.

10. Sources